Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 115,078,800
  • Shares Outstanding, K 2,624,374
  • Annual Sales, $ 24,384 M
  • Annual Income, $ 1,335 M
  • 60-Month Beta 0.44
  • Price/Sales 4.64
  • Price/Cash Flow 13.61
  • Price/Book 7.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 0.44
  • Number of Estimates 3
  • High Estimate 0.48
  • Low Estimate 0.38
  • Prior Year 0.45
  • Growth Rate Est. (year over year) -2.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.15 +21.30%
on 03/16/20
46.95 -6.60%
on 03/10/20
-3.67 (-7.72%)
since 03/06/20
3-Month
36.15 +21.30%
on 03/16/20
51.55 -14.94%
on 01/17/20
-6.10 (-12.21%)
since 01/08/20
52-Week
36.15 +21.30%
on 03/16/20
51.55 -14.94%
on 01/17/20
+2.99 (+7.32%)
since 04/08/19

Most Recent Stories

More News
Moderna to Present at 19th Annual Needham Healthcare Conference

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today...

MRNA : 32.42 (+1.25%)
AZN : 43.85 (+1.74%)
MRK : 81.62 (+3.90%)
Moderna to Host Virtual Vaccines Day on April 14, 2020

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today...

MRNA : 32.42 (+1.25%)
AZN : 43.85 (+1.74%)
MRK : 81.62 (+3.90%)
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - April 06, 2020

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income...

ABBV : 78.56 (+4.20%)
AZN : 43.85 (+1.74%)
AFL : 37.77 (+5.77%)
The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck

The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck

JNJ : 143.26 (+4.20%)
SNY : 45.18 (+1.30%)
AZN : 43.85 (+1.74%)
MRK : 81.62 (+3.90%)
LLY : 146.22 (+3.06%)
Glaxo's Nasal Polyps Study on Nucala Meets Primary Endpoints

Glaxo's (GSK) phase III study on Nucala in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) meets co-primary endpoints.

REGN : 512.33 (+2.16%)
SNY : 45.18 (+1.30%)
AZN : 43.85 (+1.74%)
GSK : 38.08 (+1.47%)
Global Psoriasis Therapeutics Market 2020 Industry Analysis, Key Players Data, Share, Size, Growth Factors, Opportunities and Forecast to 2026

The report titled by is an amazing compilation of important studies that examines the competitive landscape, segmentation, geographic expansion, and sales growth, production and consumption of the global...

AZN : 43.85 (+1.74%)
LLY : 146.22 (+3.06%)
MRK : 81.62 (+3.90%)
VRX.TO : 30.80 (-3.33%)
Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates

J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.

JNJ : 143.26 (+4.20%)
SNY : 45.18 (+1.30%)
AZN : 43.85 (+1.74%)
PFE : 34.60 (+2.95%)
MRK : 81.62 (+3.90%)
LLY : 146.22 (+3.06%)
BMY : 58.25 (+2.37%)
Sanofi to Withdraw Zantac After FDA Warns of Carcinogens

The FDA requests drugmakers to withdraw all ranitidine medications, which includes Sanofi's (SNY) popular heartburn drug Zantac, due to possible increase in risk of cancer.

SNY : 45.18 (+1.30%)
AZN : 43.85 (+1.74%)
PRGO : 48.85 (+3.76%)
LCI : 7.33 (+2.37%)
RedHill Biopharma Completes Acquisition of Movantik(R) from AstraZeneca

RedHill to promote Movantik in the U.S. to expanded call points, including gastroenterologists, primary care physicians and additional specialists, along with Talicia and Aemcolo

AZN : 43.85 (+1.74%)
RDHL : 6.16 (+0.98%)
BMY or AZN: Which Is the Better Value Stock Right Now?

BMY vs. AZN: Which Stock Is the Better Value Option?

BMY : 58.25 (+2.37%)
AZN : 43.85 (+1.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade AZN with:

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 44.87
1st Resistance Point 44.36
Last Price 43.85
1st Support Level 43.09
2nd Support Level 42.33

See More

52-Week High 51.55
Fibonacci 61.8% 45.67
Fibonacci 50% 43.85
Last Price 43.85
Fibonacci 38.2% 42.03
52-Week Low 36.15

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar